Insulin autoimmune syndrome

Marina Yukina1, Nurana Nuralieva1, Maksim Solovyev1, Ekaterina Troshina1,2 and Evgeny Vasilyev3

1Department of Therapeutic Endocrinology, Endocrinology Research Centre (ERC), Moscow, Russia, 2Russian Academy of Sciences, Endocrinology Service, Department of Therapeutic Endocrinology, Endocrinology Research Centre (ERC), Moscow, Russia, and 3Laboratory of Inherited Endocrine Disorders, Endocrinology Research Centre (ERC), Moscow, Russia

Summary

Insulin autoimmune syndrome (Hirata’s disease) is a disorder caused by development of autoantibodies to insulin and manifested by hypoglycaemic syndrome. The overwhelming majority of physicians do not include it in the differential diagnosis of hypoglycaemic states because of a misconception of an extremely low prevalence of this condition. This results in unnecessary drug therapy and unjustified surgical interventions in patients that otherwise would be successfully treated conservatively. This disease is strongly associated with certain alleles of the HLA gene. In most cases, this condition develops in predisposed individuals taking drugs containing sulfhydryl groups. Formation of autoantibodies to insulin may be observed in patients with other autoimmune disorders, as well as in those with multiple myeloma or monoclonal gammopathy of undetermined significance. This paper presents the first Russian case report of insulin autoimmune syndrome in an adult patient.

Learning points:

- Insulin autoimmune syndrome, Hirata’s disease, anti-insulin antibodies, and hypoglycaemia.

Background

Insulin autoimmune syndrome (IAS, Hirata’s disease) is one of the causes of hypoglycaemic syndrome and is due to formation of autoantibodies to immunoreactive insulin (IRI-Ab). Hypoglycaemic syndrome is a complex of symptoms associated with decreased blood glucose levels (hypoglycaemia) and neuroglycopenic symptoms and relieved by the administration of glucose. Severe hypoglycaemia is a life-threatening condition due to high risk of hypoglycaemic coma and a fatal outcome.

Formation of IRI-Ab may be observed in patients with other autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus (SLE), or polymyositis (1, 2)), multiple myeloma, or monoclonal gammopathy. Furthermore, there have been cases where hypoglycaemic syndrome was the first manifestation of a haematological disease.

Autoimmune processes have been shown to be related to certain antigens of major histocompatibility complex (MHC). IAS is known to be strongly associated with allele DRB1*04:06 and, to a lesser extent, with alleles DRB1*04:03 and DRB1*04:07. This association is believed to be attributable to essential glutamine at position 74 (shared by all three alleles) and serine at position 37 (unique to DRB1*04:06) greatly increases an individual’s predisposition to the disease (3). All the aforementioned variants belong to the increased-risk haplotype DRB1*04, DQA1*03:01, and DQB1*03:02.

Most IAS cases have been described in Japan (380 patients (4)) (5) and in other East Asian countries (including 142 cases in China (6)), which can probably be explained by the high frequency of the DRB1*04:06 allele in these populations. In Europe and America, the incidence of the disease is lower (70 patients with IAS have been reported (7)), as the DRB1*04:06 allele is extremely rarely observed and predisposition is mainly linked to...
DRB1*04:03 (8). No cases of IAS in adult patients have been described in Russia, most probably due to the fact that most physicians do not include IAS in the differential diagnosis of hypoglycaemia. Besides, mild cases of this disease often remain undiagnosed. It is thus assumed that the prevalence of this condition is significantly higher.

In over 50% of all cases, the development of IAS is preceded by use of drugs containing sulfhydryl groups (6) (Table 1). IAS usually develops a few weeks after the start of drug therapy: IRI-Ab begin to form during this period as a result of increased immunogenicity of the hormone due to a change in its molecular structure, which results from breakage of the disulfide bonds of insulin by the sulfhydryl groups of the drug substance (9).

Hypoglycaemia associated with IAS usually develops 3–4 h after meals, following an early postprandial hyperglycaemia. The increasing glucose level is most probably due to rapid binding of insulin by the antibodies during the postprandial phase, which leads to decreased biological activity of the hormone. This, in turn, results in prolongation of insulin secretion. The forming complex dissociates 3–5 h after the meal, releasing a considerable amount of insulin that causes hypoglycaemia (9). Laboratory tests performed at the peak hypoglycaemia reveal extremely high levels of insulin, C-peptide, and proinsulin (10, 11).

Most attacks of hypoglycaemia in patients with IAS are transient and resolve spontaneously 3–6 months after diagnosis, particularly quickly after discontinuation of the culprit drug. Insulin and IRI-Ab levels gradually decrease. Besides, frequent meals with a low content of complex carbohydrates and containing no simple carbohydrates (9, 12, 13) are effective, allowing to decrease postprandial hyperglycaemia and, consequently, insulin release (9). Plasmapheresis, chemotherapy, or glucocorticoid therapy are required in rare cases (such as myeloma) (5). Nevertheless, there have been cases where patients were even treated with surgery (partial pancreatectomy) due to the physicians’ poor knowledge of IAS (14, 15).

IAS should be differentiated from another form of autoimmune hypoglycaemic syndrome, type B insulin resistance. This disease is caused by stimulation of insulin receptors by antibodies (rI-Ab). The exact prevalence of this disease is unknown (16); the literature describes approximately 50 such patients in total (12). The disease is usually found in women with other autoimmune disorders (most commonly SLE); besides, it occurs as a manifestation of a paraneoplastic syndrome in patients with multiple myeloma or Hodgkin’s disease. African Americans are more frequently affected (17).

Patients with this syndrome are usually erroneously diagnosed with type 2 diabetes mellitus (18), less frequently with type 1 diabetes (19), as hyperglycaemia is often observed at the onset of the disease. Acanthosis nigricans in the axillary and inguinal regions, the neck, around the eyes (17), and around the mouth (14) is a typical, frequently seen feature of this condition. Laboratory tests reveal significantly (more than 200 μU/mL) elevated insulin levels and normal triglyceride concentrations (in contrast to other insulin resistance syndromes) (17). Women often have enlarged ovaries and elevated testosterone levels.

### Table 1 Medicinal products inducing IAS.

| Medicinal product | Percentage of the product-induced cases in the total number of IAS cases in China |
|-------------------|--------------------------------------------------------------------------------|
| Methimazole       | 64.5                                                                           |
| Insulin           | 11.2                                                                           |
| Tiopronin         | 6.4                                                                            |
| Propylthiouracil  | 4.8                                                                            |
| Penicillamine     | 2.4                                                                            |
| Alpha-lipoic acid | 1.6                                                                            |
| Amlodipine        | 1.6                                                                            |
| Captopril         | 1.6                                                                            |
| Carbimazole       | 0.8                                                                            |
| Propranolol       | 0.8                                                                            |
| Anti-tuberculosis drugs | 0.8                          |
| Pyritinol         | 0.8                                                                            |
| 131I              | 0.8                                                                            |

Adapted from Zeng et al. (6).

### Table 2 Examination at the local facility.

|                      | December 28, 2017* | January 09, 2017* | January 29, 2018* | February 2018† | Reference interval       |
|----------------------|--------------------|-------------------|-------------------|----------------|--------------------------|
| Insulin, pmol/L      | >4167              | >4167             | 3634              | 809            | 16.0–183.3               |
| Glucose, mmol/L      | 4.2                | 3.85              | 4.24              | 4             | <6.1; 3.89–5.83b          |
| HbA1C, %             | 5.4                |                   |                   |                | 4.6                      |
| C-peptide, nmol/L    | 1.379              |                   | 0.755             | 6.1           | <1.73; 0.4–1.5d          |
| Proinsulin, pmol/L   | 9.16               |                   | 6.1               |                | <4.3                     |

*After overnight fast; †After prolonged fasting test; ‡Reference interval <6.1 refers to analysis of December 28, 2017; §Reference interval of 3.89-5.83 refers to other analyses; †Reference interval <1.73 refer to analysis of January 29, 2018; ‡Reference interval 0.4–1.5 refers to analysis of February 2018.
According to Arioglu et al., one-third of patients with type B insulin resistance develop a spontaneous remission within 11–48 months. Otherwise, the patient requires pharmacological therapy (hypoglycaemia should be treated with glucocorticoids, cyclosporin A, azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab (17, 18, 19, 20, 21); besides, some patients are treated with plasmapheresis (17, 18, 19)); however, a remission can be achieved only in 50% of cases (17). Mortality rates are high (18): up to 54% of patients die within 10 years after diagnosis (21). The unfavourable prognosis is both due to the underlying condition and severe hypoglycaemic episodes (19).

In 2017, Kuznetsova et al. made the first Russian description of a case of IAS in a 3.5-year-old Caucasian girl, which was possibly caused by a previous course of pyritinol therapy. The authors pointed to the need of inclusion of IAS in the differential diagnosis of hypoglycaemic syndrome (after excluding iatrogenic hypoglycaemias and organic hyperinsulinism) in all patients with atypical clinical presentation combined with extremely high insulin levels and anti-insulin autoantibodies forming without previous insulin therapy (22).

Case presentation

Patient A, female, 46 years old, was evaluated at the Endocrinology research Centre in April 2018. The patient reported episodes of dizziness, sense of fear, and ‘creeping’ sensations occurring 2–3 h after meals and associated with blood glucose reductions to a minimum 2.1 mmol/L. The patient’s medical history revealed that these attacks first developed in December 2017, a week after discontinuation of alpha-lipoic acid (the patient received this drug for polyneuropathy of the lower limbs in November 2017). The last attack occurred at the February 2018.

The patient was examined several times at her local facility (Table 2): blood tests performed after an overnight fast revealed no evidence of hypoglycaemia; however, a significant increase in insulin levels and a moderate elevation of proinsulin were observed. In February 2018, the patient underwent a prolonged fasting test, which was discontinued after 72 h since the blood glucose concentrations were normal. A significant increase in insulin levels was also
observed after the test, but IRI-Ab and rI-Ab levels were still not measured. As insulinoma was suspected, abdominal ultrasonography and MRI were performed and demonstrated no evidence of a mass lesion in the pancreas.

Concomitant diseases included grade II obesity (BMI 36.0 kg/m$^2$), dyslipidaemia, hyperuricaemia, cholelithiasis, hiatal hernia, and mixed gastritis (superficial and erosive). In 2016, the patient had surgery (removal of the uterus and ovaries) for bilateral contained pyosalpinx, ovarian abscess, and endomyometritis. Besides, in September 2017, the patient had surgery for discitis, which was followed by a 2-month antibacterial therapy that included Ciprofloxacin, Doxycycline, and Metronidazole. There is no family history of autoimmune diseases.

In April 2018, the patient was first evaluated at the Endocrinology Research Centre. Physical examination revealed no signs of hyperandrogenism or acanthosis nigricans (the serum testosterone level was also within the reference interval).

### Investigation

A continuous blood glucose monitoring system with a portable device was used to perform provocation tests with a 72-h fast (Figs 1 and 2), mixed food, physical exertion (23), and an oral glucose tolerance test (OGTT), which revealed no hypoglycaemia. However, the tests revealed significant increases in insulin and IRI-Ab both at the start and at the end of the prolonged fasting test, as well as pronounced insulin resistance (HOMA-IR = 76); HOMA was calculated using the following formula: insulin (µU/mL) × glucose (mmol/L)/22.5. They also showed a moderate increase in rI-Ab at the start of the test and normal levels at its completion.

IAS was thus suspected based on the IRI-Ab increase. The lack of evidence of hypoglycaemic syndrome at the time of examination was most probably due to the reduced IRI-Ab level long after discontinuation of a drug containing a sulfhydryl group.

After that, clinical workup was started to exclude multiple myeloma and monoclonal gammopathy, two possible causes of elevated IRI-Ab. The total protein, calcium, creatinine concentrations, and complete blood count results were within reference intervals. Serum and urine immunochemistry with free light chain determination (Figs 3 and 4) was performed and revealed no pathological gradients or abnormal free light chain ratios. Serum protein electrophoresis results (Table 3) revealed an increase in polyclonal IgA, whereas the concentrations of other immunoglobulins were found to be within reference intervals. Concentrated urine protein tests demonstrated traces of albumin and no Bence-Jones protein (including highly sensitive immunofixation analysis). Therefore, no evidence of multiple myeloma or monoclonal gammopathy was obtained.

Additionally, in view of the IRI-Ab increase, we performed HLA-typing and revealed DRB1*03-DQA1*05:01-DQB1*02/DRB1*04-DQA1*03:01-DQB1*03:02 genotype (Table 4). The presence of a DRB1*04 allele in a high-risk haplotype was shown, which is consistent with data reported by most authors. However, as high-definition genotyping of DRB1 alleles was not carried out, the specific DRB1*04 allele is unknown. DRB1*03 detected in IAS has already been reported in a publication (24).

Therefore, the medical history data (association between hypoglycaemia episodes and use of thioctic acid) and results of laboratory and genetic tests led to the diagnosis of IAS induced by a drug containing a sulfhydryl group.

### Table 3  Serum protein immunochemistry.

| Test               | Value | Units | Reference interval |
|--------------------|-------|-------|--------------------|
| IgG, IU/mL         | 192   | IU/mL | 95–235             |
| IgA, IU/mL         | 290   | IU/mL | 55–250             |
| IgM, IU/mL         | 183   | IU/mL | 60–405             |
| κ/λ                | 2.2   | -     | 1.1–2.9            |
| Cryoglobulins      | negative | - | negative          |
| κ-FLC mg/L         | 11.7  | mg/L  | 3.3–19.4           |
| λ-FLC mg/L         | 15.3  | mg/L  | 5.7–26.3           |
| κ/λ-FLC            | 0.76  | -     | 0.26–1.65          |

*Free light chains.

### Table 4  HLA-typing.

| HLA-DRB1*03 | HLA-DQA1*05:01 | HLA-DQB1*02 | HLA-DRB1*04 | HLA-DQA1*03:01 | HLA-DQB1*03:02 |
|-------------|----------------|-------------|-------------|----------------|----------------|
| DRB1*03     | DQA1*05:01     | DQB1*02     | DRB1*04     | DQA1*03:01     | DQB1*03:02     |

Downloaded from Bioscientifica.com at 09/15/2023 12:06:49AM via free access
group (alpha-lipoic acid). Type B insulin resistance was ruled out based on the minor increase in rI-Ab and the absence of hyperandrogenism and *acanthosis nigricans*.

As the patient was diagnosed with IAS, she underwent immunological examination to exclude a predisposition to other autoimmune disorders of the endocrine system: adrenal insufficiency, autoimmune thyroid disorders, and diabetes mellitus (Table 5). As the table shows, levels of all evaluated antibodies were within reference intervals. Although the levels of antibodies to TPO, TG, and rTSH were not increased, thyroid ultrasonography demonstrated signs of autoimmune damage. Follow-up was recommended in view of a normal TSH level (1.39 \( \mu \)IU/mL).

### Table 5 Immunological tests.

| Test                                             | Value   | Units   | Reference interval |
|--------------------------------------------------|---------|---------|--------------------|
| Antibodies to 21-hydroxylase                      | 0.028   | U/mL    | <0.4               |
| Antibodies to thyroid peroxidase (TPO)            | 0.8     | IU/mL   | 0–5.6              |
| Abnormalities to thyroglobulin (TG)               | 10      | IU/mL   | 0–115              |
| Antibodies to thyroid-stimulating hormone receptor (rTSH) | 0.3 | IU/L    | 0–1.75             |
| Antibodies to pancreatic glutamic acid decarboxylase | 0.3  | U/mL    | 0–1                |
| Antibodies to pancreatic islet cells              | 0.23    | U/mL    | 0–1                |
| Antibodies to tyrosine phosphatase                | 0.6     | U/mL    | 0–10               |
| Antibodies to zinc transporter                    | 10      | U/mL    | 0–15               |

**Treatment**

The patient was also advised to avoid (unless vitally indicated) using drugs that can potentially trigger formation of IRI-Ab. No drug therapy was administered for IAS and no dietary adjustment was used either, as the syndrome had resolved spontaneously. Recommendations included blood glucose determination with a blood glucose monitor when the patient felt unwell.

**Outcome and follow-up**

Episodes of hypoglycaemia did not recur within 10 months after discharge from the hospital. A follow-up evaluation performed after an overnight fast revealed a gradual reduction in the levels of insulin and IRI-Ab (Fig. 5 and Table 6) and decreased insulin resistance (HOMA-IR=31). Follow-up of the patient continues.

### Table 6 Test results obtained after discharge from the Endocrinology Research Centre after an overnight fast.

| Test            | July 18, 2018 | November 26, 2018 | February 28, 2019 | Reference interval |
|-----------------|--------------|-------------------|-------------------|--------------------|
| Insulin, pmol/L | 1293.75      | 993.75            | 636.74            | 16.0–183.3         |
| Glucose, mmol/L | 4.89         | 4.87              | 5.63              | 3.1–6.1            |
| C-peptide, nmol/L | 1.37       | 1.63              | 1.49              | 0.4–1.5            |
| IRI-Ab, U/mL    | 66.15        | 35.26             | 23.9              | <10                |
| rI-Ab, ng/mL    | 4.94         | 0.823             | 0.238             | <3.65              |

**Discussion**

Therefore, IAS should be ruled out in all patients with hyperinsulinaemic hypoglycaemia to facilitate further determination of an adequate strategy of clinical evaluation, treatment, and follow-up. Diagnosis of this condition requires detailed interview on the use of implicated drugs and careful analysis of the clinical findings and laboratory test results. Pancreatic imaging is not required in patients with IAS. It should also be taken into consideration that autoimmune hypoglycaemia

https://edm.bioscientifica.com/
may be the first manifestation of severe haematological and autoimmune diseases, and therefore patients in this cohort should undergo in-depth evaluation.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

Funded by a grant from the Russian Science Foundation (project 17-75-30035).

Patient consent

Written informed consent has been obtained from the patient for the publication of this article.

Author contribution statement

Yukina Marina, Nuralieva Nurana, Soloyev Maksim, Troshina Ekaterina, and Vasilyev Evgeny performed case study and wrote the article.

References

1 Li JK, Lee WK, Chan CH, Ng R & Wong BK. Auto-insulin antibodies due to methimazole in a patient with Myasthenia Gravis and Graves disease. Annals of Gerontology and Geriatric Research 2015 2 1021–1022.
2 Rouabhia S, Ramanoelina J, Godmer P, Reach G, Dutel JL & Guillevin L. Insulin autoimmune syndrome revealing systemic lupus erythematosus. Annales de Medecine Interne 2003 154 59–60.
3 Censi S, Mian C & Betterle C. Insulin autoimmune syndrome: from diagnosis to clinical management. Annals of Translational Medicine 2018 6 335. (https://doi.org/10.21037/atm.2018.07.32)
4 Lichtman MA & Balderman SR. Unusual manifestations of essential monoclonal gammapathy. II. Simulation of the insulin autoimmune syndrome. Rambam Maimonides Medical Journal 2015 6 e0027. (https://doi.org/10.5041/RMMJ.10212).
5 Zhang Y & Zhao T. Hypoglycemic coma due to insulin autoimmune syndrome induced by methimazole: a rare case report. Experimental and Therapeutic Medicine 2014 8 1581–1584. (https://doi.org/10.3892/etm.2014.1964)
6 Zeng XX, Tang YJ, Hu KX, Wang J, Zhu LY, Liu JY & Xu J. Insulin autoimmune syndrome in a pregnant female: a rare case report. Medico 2017 96 1–3. (https://doi.org/10.1097/MID.0000000000009213)
7 Ismail AAA. The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis. Clinical Chemistry and Laboratory Medicine 2016 54 1715–1724. (https://doi.org/10.1515/cclm-2015-1255).
8 Gullo D, Evans JL, Sortino G, Goldfine ID & Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking e-lipoic acid. Clinical Endocrinology 2014 81 204–209. (available at: https://www.ncbi.nlm.nih.gov/pubmed/24111525) (https://doi.org/10.1111/cen.12334).
9 Rajpal A, Kassem LS, Moscoso-Cordero M & Arafah BM. Clopidogrel-induced insulin autoimmune syndrome: a newly recognized cause of hypoglycemia in a patient without diabetes. Journal of the Endocrine Society 2017 1 1217–1223. (https://doi.org/10.1210/js.2017-00316).
10 Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE & Gorden P. Treatment of Type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. Journal of Clinical Endocrinology and Metabolism 2010 95 3641–3647. (https://doi.org/10.1210/jc.2010-0167).
11 Azamendi AE, Rajamani U & Jialal I. Pseudoinsulinoma in a white man with autoimmune hypoglycemia due to anti-insulin antibodies value of the free C-peptide assay. American Journal of Clinical Pathology 2014 142 689–693. (https://doi.org/10.1309/AJCPX56JQ8JHUBGJ).
12 Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK & Gorden P. Autoimmune forms of hypoglycemia. Medicine 2009 88 141–153. (https://doi.org/10.1097/MD.0b013e3181a5b42e).
13 Wong SL, Priestman A & Holmes DT. Recurrent hypoglycemia from insulin autoimmune syndrome. Journal of General Internal Medicine 2014 29 250–254. (https://doi.org/10.1007/s11606-013-2588-9).
14 Masjhar JS. Insulin autoimmune syndrome (Hirata’s disease): severe hypoglycemic episodes in Graves’ hyperthyroidism patient treated with methimazole. Acta Medica Indonesiana 2005 37 214–217.
15 Uchigata Y & Hirata Y. Insulin autoimmune syndrome (Hirata disease). In Immunonendocrinology: Scientific and Clinical Aspects, pp. 343–368. Ed Eisenbarth. Humana Press, 2011.
16 Orphanet: the portal for rare diseases and orphan drugs. [Internet]. (available at: http://www.orpha.net/consor/cgi-bin/OC_Exp. Php?L=GB&Expert=229).
17 Arioglu E, Andewalt A, Diabo C, Bell M, Taylor SL & Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine 2002 81 87–100. (https://doi.org/10.1097/00005792-200203000-00001).
18 Viswanathan L & Sirisena I. Immunosuppressive therapy in treatment of refractory hypoglycemia in Type B insulin resistance: a case report. Journal of the Endocrine Society 2017 1 1435–1439. (https://doi.org/10.1210/js.2017-00292).
19 Shanker K, Daley T, Semple R, Rouster-Stevens K & Ham JN. Intractable hypoglycemia in the setting of autoimmune overlap syndrome. Pediatrics 2017 139 e20160866. (https://doi.org/10.1542/peds.2016-0866).
20 Chon S, Choi MC, Lee VJ, Hwang YC, Jeong IK, Oh S, Ahn KJ, Chung HY, Woo JT, Kim SW, et al. Autoimmune hypoglycemia in a patient with characterization of insulin receptor autoantibodies. Diabetes and Metabolism Journal 2011 35 80–85. (https://doi.org/10.4093/dmj.2011.35.1.180).
21 Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE & Gorden P. Treatment of Type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. Journal of Clinical Endocrinology and Metabolism 2010 95 3641–3647. (https://doi.org/10.1210/jc.2010-0167).
22 Kuznetsova ES, Filipenko OV & Melikyan MA. Insulin autoimmune syndrome: a rare cause of hypoglycemia. The case report of the syndrome in pediatric practice. Problems of Endocrinology 2017 63 189–194. (https://doi.org/10.14341/probl2017633189-194).
23 Gama R, Teale JD & Marks V. Best practice no 173: clinical and laboratory investigation of adult spontaneous hypoglycaemia. Journal of Clinical Pathology 2003 56 641–646. (https://doi.org/10.1136/jcp.56.9.641).
24 Sahni P, Trivedi N & Omer A. Insulin autoimmune syndrome: a rare cause of postprandial hypoglycemia. Endocrinology, Diabetes and Metabolism Case Reports 2016 2016 16-0064. (https://doi.org/10.1530/EDM-16-0064).

Received in final form 14 April 2020
Accepted 28 April 2020